Gilead Sciences (GILD)

Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.

HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.

Compare fees, diversification, and risk between these two leading healthcare ETFs.

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market capitalization of

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.

It may not duplicate those impressive results, but it has all the tools it needs.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova...

Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short o...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks.

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the